temic pull-back of the pharmaceutical industry from research and development of new treatments for schizophrenia.With the advent of successful methods for identifying anomalies at the genetic level, schizophrenia and other neuropsychiatric disorders stand to benefit immensely from incorporating these approaches and broadening our understanding of the pathogenesis of these illnesses.???Advancing Dr